Our Proprietary Technologies
For more than a century, the Ajinomoto Group has pioneered science to solve complex challenges and create new possibilities for people, society, and the planet. That legacy of scientific rigor, R&D excellence, and continuous innovation has led to proprietary technologies designed to address specific challenges across biopharma, including AJIPHASE™, AJICAP™, CORYNEX™, and enzymatic ligation technologies. Explore our technologies below.
AJICAP™
Enhances stability and yield in antibody conjugates through site-specific conjugation and linker technology.
AJIPHASE™
Advances scalable, sustainable oligonucleotide and peptide synthesis through hybrid liquid-phase production.
CORYNEX™
Enables simplified, efficient protein and long peptide production through microbial secretory expression.
Enzymatic Ligation
Enzymatic ligation builds a full-length RNA from short, high-purity fragments joined by an enzyme. We apply this approach in two ways: enzymatic siRNA synthesis for GMP-grade siRNA from several kilograms up to 200 kg, and GenClip™ for long RNA from 100 to 500 mer.
Find the Right Technology for Your Program
Explore how our proprietary technologies can help address your specific development and manufacturing challenges.